Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study

PLoS ONE - United States
doi 10.1371/journal.pone.0058438
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)

PLoS ONE
Multidisciplinary
2013English

Lidocaine for Systemic Sclerosis: A Double-Blind Randomized Clinical Trial

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial

Neurology
Neurology
2015English

A Selective Neurokinin-1 Receptor Antagonist in Chronic PTSD: A Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial

European Neuropsychopharmacology
PsychiatryMental HealthNeurologyBiological PsychiatryPharmacology
2011English

Double Blind Study of Intrathecal Beta-Interferon in Multiple Sclerosis: Clinical and Laboratory Results.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1990English

Multiple Sclerosis: Longitudinal Measurement of Interleukin-1 Receptor Antagonist.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1997English

A Randomized Double Blind Study of a Green and Black Tea Agent, AssuriTEA®, in Healthy Male Subjects

Functional Foods in Health and Disease
2015English

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis

Kidney International Reports
Nephrology
2017English

Eptinezumab in Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study (PROMISE-1)

Cephalalgia
MedicineNeurology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy